INTEGRATED APPROACH TO THE ISOLATION AND PURIFICATION OF ANTIBODIES
Disclosed herein is an integrated approach to purification process development and execution, including processes comprising particular capture and fine purification steps; processes that employ of a minimal number of buffer systems, and processes that make use of minimally-corrosive buffer systems, as well as combinations thereof.
1 . A method for producing a host cell protein-reduced antibody preparation from a sample mixture comprising an antibody and at least one host cell protein, said method comprising:
(a) contacting said sample mixture with a loading buffer and contacting said loading buffer and sample mixture to a capture separation chromatographic support under conditions where said antibody is retained on said chromatographic support;
(b) washing said capture separation chromatographic support with a wash buffer to remove the sample mixture components that are not retained on said capture separation chromatographic support; and
(c) contacting said capture separation chromatographic support with an elution buffer to thereby produce a capture separation eluate;
wherein said loading, wash, and elution buffers consist of water and essentially the same anion and cation components; and
wherein said capture separation eluate comprises said host cell protein-reduced antibody preparation.
2 . The method of claim 1 , wherein said anion and cation components are selected from the group consisting of Tris and Citrate, Tris and Acetate, Trolamine and Citrate, and Trolamine and Acetate.
3 . The method of claim 1 , wherein said capture separation chromatography support is a Protein A resin selected from the group consisting of a MabSelect™ resin (GE Healthcare), MabSelect Sure™ resin (GE Healthcare), and ProSep Ultra Plus (Millipore).
4 . The method of claim 1 , comprising the steps of:
(d) contacting said capture separation eluate to a loading buffer and contacting said capture separation eluate and loading buffer mixture to a fine purification separation chromatographic support capable of further reducing the host cell protein content of the capture separation eluate; and
(e) washing said fine purification chromatographic support with a wash buffer to remove the capture separation eluate components that are not retained on said fine purification chromatographic support; and
(f) contacting said fine purification chromatographic support with an elution buffer to thereby produce a fine purification separation eluate
wherein the capture separation and fine purification separation load, wash, and elution buffers consist of water and essentially the same anion and cation components selected from the group consisting of Tris and Citrate, Tris and Acetate; Trolamine and Citrate; and Trolamine and Acetate
5 . The method of claim 4 wherein said fine purification separation chromatographic support is an ion exchange matrix selected from the group consisting of an anion exchange matrix and a cation exchange resin; a mixed mode resin or a hydrophobic interaction resin.
6 . The method of claim 5 , wherein said ion exchange matrix is a cation exchange resin selected from the group consisting of Fractogel, carboxymethyl (CM), sulfoethyl(SE), sulfopropyl(SP), phosphate(P), sulfonate(S), Nuvia S (BioRad), Capto S (GE Healthcare) and Gigacap S (Tosoh); or an anion exchange matrix selected from the group consisting of Q sepharose, diethylaminoethyl (DEAE), quaternary aminoethyl(QAE), quaternary amine(Q) groups, Q Sepharose FF (GE Healthcare), Toyopearl QAE 550C (Tosoh), Poros 50HQ (Applied Biosystems), Poros 50PI (Applied Biosystems), Sartobind Q (Sartorius), ChromaSorb Q (Millipore) and Mustang Q (Pall).
7 . The method of claim 5 , wherein said chromatographic support is a mixed mode resin selected from the group consisting of Capto-Adhere™ (GE Healthcare), HEA—HyperCel (hexylamine) and PPA-HyperCel (propylphenyl amine) (Pall); a hydrophobic interaction resin selected from the group consisting of alkyl-, aryl-groups, Phenyl Sepharose, Phenyl Sepharose™ 6 Fast Flow column, Phenyl Sepharose™ High Performance column, Octyl Sepharose™ High Performance column, Fractogel™ EMD Propyl, Fractogel™ EMD Phenyl columns, Macro-Prep™ Methyl, Macro-Prep™ t-Butyl Supports, WP HI-Propyl (C 3 )™ column, Toyopearl™ ether, phenyl or butyl columns and a combination thereof.
8 . The method of claim 1 further comprising a depth filtration step, a viral inactivation step selected from the group consisting of a viral filtration step and a pH-mediated viral inactivation step, or a combination thereof.
9 . A method for developing an integrated purification protocol for producing host cell-reduced preparations from two sample mixtures where each sample mixture comprises a distinct antibody and at least one host cell protein:
(a) selecting a capture separation chromatographic support capable of retaining the distinct antibodies of said sample mixtures; and
(b) selecting load, wash, and elution buffers for, respectively, loading, washing, and production of a capture separation eluate;
wherein said loading, wash, and elution buffers consist of water and essentially the same anion and cation components; and
wherein said capture separation eluate comprises said host cell protein-reduced antibody preparation.
10 . The method of claim 9 , wherein said anion and cation components are selected from the group consisting of Tris and Citrate, Tris and Acetate, Trolamine and Citrate, and Trolamine and Acetate.
11 . The method of claim 9 , wherein said capture separation chromatography support is a Protein A resin selected from the group consisting of MabSelect™ resin (GE Healthcare), MabSelect Sure™ resin (GE Healthcare), and ProSep Ultra Plus (Millipore).
12 . The method of claim 11 , further comprising the steps of:
(c) selecting a fine purification separation chromatographic support capable of further reducing the host cell protein content of the capture separation eluate; and
(d) selecting load, wash, and elution buffers for, respectively, loading, washing, and production of a fine purification separation eluate;
wherein the capture separation and fine purification separation buffers consist of water and essentially the same anion and cation components selected from the group consisting of Tris and Citrate, Tris and Acetate, Trolamine and Citrate, and Trolamine and Acetate.
13 . The method of claim 12 wherein said fine purification separation chromatographic support is an ion exchange matrix selected from the group consisting of an anion exchange matrix or a cation exchange resin.
14 . The method of claim 13 , wherein said ion exchange resin is a cation exchange resin selected from the group consisting of Fractogel, carboxymethyl (CM), sulfoethyl(SE), sulfopropyl(SP), phosphate(P), sulfonate(S), Nuvia S (BioRad), Capto S (GE Healthcare) and Gigacap S (Tosoh); or an anion exchange matrix selected from the group consisting of Q sepharose, diethylaminoethyl (DEAE), quaternary aminoethyl(QAE), quaternary amine(Q) groups, Q Sepharose FF (GE Healthcare), Toyopearl QAE 550C (Tosoh), Poros 50HQ (Applied Biosystems), Poros 50PI (Applied Biosystems), Sartobind Q (Sartorius), ChromaSorb Q (Millipore) and Mustang Q (Pall).
15 . The method of claim 12 , wherein said fine purification separation chromatographic support is a mixed mode resin or a hydrophobic interaction resin.
16 . The method of claim 15 , wherein said chromatographic support is a mixed mode resin selected from the group consisting of Capto-Adhere™ (GE Healthcare), HEA—HyperCel (hexylamine) and PPA-HyperCel (propylphenyl amine) (Pall); or a hydrophobic interaction resin selected from the group consisting of alkyl-, aryl-groups, phenyl sepharose, Phenyl Sepharose™ 6 Fast Flow column, Phenyl Sepharose™ High Performance column, Octyl Sepharose™ High Performance column, Fractogel™ EMD Propyl, Fractogel™ EMD Phenyl columns, Macro-Prep™ Methyl, Macro-Prep™ t-Butyl Supports, WP HI-Propyl (C 3 )™ column, and Toyopearl™ ether, phenyl or butyl columns, and a combination thereof.
17 . The method of claim 11 further comprising a depth filtration step, a viral inactivation step selected from the group consisting of a viral filtration step and a pH-mediated viral inactivation step, or a combination thereof.
18 . A method for producing a host cell protein-reduced antibody preparation from a sample mixture comprising an antibody and at least one host cell protein, said method comprising;
(a) contacting said sample mixture with a loading buffer and contacting said loading buffer and sample mixture to a capture separation chromatographic support under conditions where said antibody is retained on said chromatographic support;
(b) washing said capture separation chromatographic support with a wash buffer to remove the sample mixture components that are not retained on said capture separation chromatographic support;
(b) contacting said capture separation chromatographic support with an elution buffer to thereby produce a capture separation eluate comprising said antibody;
(c) contacting said capture separation eluate to a second capture separation chromatographic support under conditions where said antibody is retained on said second capture separation chromatographic support, wherein said second capture separation chromatographic support is selected from the group consisting of an ion exchange matrix, a mixed mode resin and a hydrophobic interaction resin; and
(d) contacting said second capture separation chromatographic support with an elution buffer to thereby produce a second capture separation eluate,
wherein said loading, wash, and elution buffers consist of water and essentially the same anion and cation components; and
wherein said second capture separation eluate comprises said host cell protein-reduced antibody preparation.
19 . The method of claim 18 , wherein said anion and cation components are selected from the group consisting of Tris and Citrate, Tris and Acetate, Trolamine and Citrate, and Trolamine and Acetate.
20 . The method of claim 18 further comprising a depth filtration step, a viral inactivation step selected from the group consisting of a viral filtration step and a pH-mediated viral inactivation step, or a combination thereof.